Rako Science, a Kiwi company that provides COVID-19 PCR saliva testing, and Thermo Fisher Scientific, the world leader in serving science, today announced they have entered a strategic partnership to support asymptomatic surveillance testing for COVID-19.
“Thermo Fisher’s COVID-19 support has been a critical component of Rako Science’s success so far and means rapid and accurate saliva testing will become more widely available in our region,” Rako chief science officer Dr Stephen Grice said.
“Sectors such as education, sports and entertainment are all looking for ways to prevent COVID outbreaks and PCR saliva testing is an effective way to regularly test asymptomatic people.”
“We support the efforts of Rako Science in establishing asymptomatic COVID-19 testing to support safe workplaces and entertainment, sport and education.
“The utilisation of a scientific approach provides confidence in testing solutions to support pandemic impacted sectors safely return to economic activity in the region,” said Dominic Stranieri VP/GM of Thermo Fisher Scientific Australia and New Zealand.
Background on Thermo Fisher
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Its global team of more than 80,000 colleagues delivers an unrivalled combination of innovative technologies, purchasing convenience and pharmaceutical services through its industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, visit www.thermofisher.com.